NCT03212586 is a Phase 1 clinical trial of BAY1902607 in Clinical Trials, Phase I as Topic, sponsored by Bayer.

Who is sponsoring NCT03212586?

NCT03212586 is sponsored by Bayer.

What drugs are being tested in NCT03212586?

Interventions in NCT03212586: BAY1902607, Placebo.

What condition does NCT03212586 study?

NCT03212586 studies Clinical Trials, Phase I as Topic.

Is NCT03212586 still recruiting?

NCT03212586 is currently completed. Last updated 14 May 2019.

Last reviewed 2019-05-14 · How we verify

NCT03212586

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

BAY 1902607: Single Dose Escalation, Safety and Tolerability, Pharmacokinetics, Bioavailability, Food Effect

Completed Phase 1 Last updated 14 May 2019

What this trial tests

Phase 1 trial testing BAY1902607 in Clinical Trials, Phase I as Topic in 72 participants. Completed in 27 July 2018.

Timeline

18 July 2017

Primary endpoint
3 May 2018

27 July 2018

Quick facts

Lead sponsor	Bayer
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	basic science
Enrollment	72
Start date	18 July 2017
Primary completion	3 May 2018
Estimated completion	27 July 2018
Sites	1 location across Germany

Drugs / interventions tested

BAY1902607 — full drug profile →
Placebo

Conditions studied

Clinical Trials, Phase I as Topic — all drugs for Clinical Trials, Phase I as Topic →

Sponsor

Bayer — full company profile →

Who can join

Adults 18 to 45, male only, with Clinical Trials, Phase I as Topic. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a first-in-man study that will investigate the safety, tolerability and pharmacokinetics of ascending single doses of BAY1902607 using a placebo controlled, randomized, single center design. In addition the influence of food on the pharmacokinetics of BAY1902607 and the bioavailability between different pharmaceutical formulations will be investigated

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Safety, Tolerability, and Pharmacokinetics of Filapixant, a Highly Selective P2X3 Receptor Antagonist, in an Ascending-Single-Dose First-in-Human Study.
Francke K, Baumann S, Gashaw I, Klein S, et al · · 2025 · cited 1× · PMID 40430576 · DOI 10.3390/ph18050758

Verify or expand the search:

Other trials of BAY1902607

Trials testing the same drug.

NCT03789890 — Study to Learn More About the Effect of Itraconazole (ITZ) Given Repeatedly by Mouth on the Way How the Study Drug BAY19 · Phase 1 · completed
NCT03535168 — Repeat Doses of BAY1902607 in Healthy Males and Proof of Concept in Chronic Cough Patients · Phase 1, PHASE2 · completed

Other Bayer trials

Trials by the same sponsor.

NCT05900388 — A Study to Observe the Pattern of Use and Safety of Rivaroxaban in Children Under 2 Years Old With Venous Thromboembolis · not yet recruiting
NCT07490431 — An Observational Study to Learn More About How Elinzanetant is Used and How Well it Works for Women With Menopause Sympt · not yet recruiting
NCT05477953 — An Observational Pregnancy Safety Study in Women Who Were Exposed to the Drug Nifurtimox During Pregnancy to Learn About · not yet recruiting
NCT07192952 — A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Child · Phase 3 · not yet recruiting
NCT07450599 — A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Befo · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03212586 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Bayer
Last refreshed: 14 May 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03212586.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing